Evercore ISI Downgrades Hologic to Hold Rating | GenomeWeb

NEW YORK (GenomeWeb) – Evercore ISI today downgraded Hologic's stock to a Hold rating, saying that the firm's current share price has "limited upside" to Evercore's price target of $38.50. 

The investment bank previously had a Buy rating on Hologic, and in a research note, analyst Vijay Kumar noted that while he believes that the firm's 3D tomography adoption cycle is entering its "sweet spot … we believe that the stock is appropriately pricing in the optimism, and are moving to the sidelines as we think much of our thesis has played out." 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.